Single Dose of Phosphatidylinositol 3-Kinase Inhibitor Alpelisib Induces Insulin Resistance in Healthy Adults: A Randomized Feasibility Study
Diabetes · 2024
DOI: 10.2337/db24-0402 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, 2024. Verfasst von Joshua R Cook und 5 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Endocrinology Research Center, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Columbia University Vagelos C…. Hauptthemen laut MEDLINE: Insulin Resistance, Glucose Tolerance Test, Blood Glucose, Insulin. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Division of Diabetes, Endocrinology, and Metabolic Diseases, NCATS NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Our objective was to test a single dose of the phosphatidylinositol 3-kinase (PI3K) inhibitor alpelisib as a tool for acute modeling of insulin resistance in healthy volunteers. This single-center double-blind phase 1 clinical trial randomly assigned healthy adults to a single oral dose of 300 mg alpelisib (n = 5) or placebo (n = 6) at bedtime, followed by measurement of glucose, insulin, and C-peptide levels after an overnight fast and during a 3-h 75-g oral glucose tolerance test (OGTT). Fasting plasma glucose trended higher with alpelisib (mean ± SD 93 ± 11 mg/dL) versus placebo (84 ± 5 mg/dL); mean fasting serum insulin increased nearly fivefold (23 ± 12 vs. 5 ± 3 μU/mL, respectively), and HOMA of insulin resistance (IR) scores were 5.4 ± 3.1 for alpelisib and 1.1 ± 0.6 for placebo. During OGTT, incremental area under the curve (AUC) for insulin was more than fourfold greater with alpelisib (22 ± 15 mU/mL × min) than with placebo (5 ± 2 mU/mL × min); glucose AUC trended higher with alpelisib. Single-dose alpelisib was well tolerated and produced metabolic alterations consistent with acute induction of IR, validating its use for mechanistic study of insulin action in humans. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes and Endocrinology Research Center, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY.
- Center for Liver Disease and Transplantation, Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY.
- Division of Preventive Medicine and Nutrition, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY.
ORCID-Profile: Joshua R Cook
Förderung
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- NCATS NIH HHS
- NIDDK NIH HHS
- Columbia University Department of Medicine
- National Center for Advancing Translational Sciences
Zitieren
APA
Cook, J. R., Bedeir, N., Sone, Z. D., Wattacheril, J., Ginsberg, H. N., & Laferrère, B. (2024). Single Dose of Phosphatidylinositol 3-Kinase Inhibitor Alpelisib Induces Insulin Resistance in Healthy Adults: A Randomized Feasibility Study. Diabetes. https://doi.org/10.2337/db24-0402
Vancouver
Cook JR, Bedeir N, Sone ZD, Wattacheril J, Ginsberg HN, Laferrère B. Single Dose of Phosphatidylinositol 3-Kinase Inhibitor Alpelisib Induces Insulin Resistance in Healthy Adults: A Randomized Feasibility Study. Diabetes. 2024. doi:10.2337/db24-0402
BibTeX
@article{Cook2024,
author = {Cook, Joshua R and Bedeir, Nur and Sone, Zachary D and Wattacheril, Julia and Ginsberg, Henry N and Laferrère, Blandine},
title = {Single Dose of Phosphatidylinositol 3-Kinase Inhibitor Alpelisib Induces Insulin Resistance in Healthy Adults: A Randomized Feasibility Study},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db24-0402}
}
EUVIMED